Coherus BioSciences
CHRS
$2.06
Share price
0.74%
Change (1 day)
-71.58%
Change (1 year)
Categories
Coherus BioSciences (CHRS) - P/B ratio
P/B ratio as of April 2024 : -1.20
According to Coherus BioSciences
's latest financial reports the company has a price-to-book ratio of -1.20.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Coherus BioSciences - P/B ratio (from 2014 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | -1.92 | -57.23% |
| 2022-12-31 | -4.48 | -135.75% |
| 2021-12-31 | 12.5 | 181.38% |
| 2020-12-31 | 4.46 | -62.99% |
| 2019-12-31 | 12.0 | -175.18% |
| 2018-12-31 | -16.0 | -194.65% |
| 2017-12-31 | 16.9 | -73.35% |
| 2016-12-31 | 63.5 | -149.12% |
| 2015-12-31 | -129 | -1689.68% |
| 2014-12-31 | 8.13 | |
| 2013-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 23.2 | -2,041.20% | 🇺🇸 USA |
 Repligen
RGEN | 4.72 | -494.20% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | 0.0139 | -101.16% | 🇺🇸 USA |